Atracurium Besylate Injection, Solution
Product Images NDC 71288-701

5 FDA label images from Meitheal Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Atracurium Besylate (NDC 71288-701). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Meitheal Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Atr09 0002 01)

Structural Formula (Atr09 0002 01)
Chemical structure of Atracurium Besylate showing its molecular arrangement including aromatic rings, methoxy groups, and sulfonate functional groups.*
FDA Label Image

Principal Display Panel – Atracurium Besylate Injection, Usp 50 mg Vial Label (Atr09 0002 02)

Principal Display Panel – Atracurium Besylate Injection, Usp 50 mg Vial Label (Atr09 0002 02)
Label for Atracurium Besylate Injection, USP 50 mg per 5 mL (10 mg per mL) intravenous injection by Meitheal Pharmaceuticals Inc. The vial contains 5 mL. The label includes a warning that the drug is a paralyzing agent causing respiratory arrest, and must be used with artificial respiration available. Storage instructions and manufacturer details are also present, along with barcodes and space for lot and expiration dates.*
FDA Label Image

Principal Display Panel – Atracurium Besylate Injection, Usp 50 mg Carton (Atr09 0002 03)

Principal Display Panel – Atracurium Besylate Injection, Usp 50 mg Carton (Atr09 0002 03)
Packaging label for Atracurium Besylate Injection, USP 50 mg per 5 mL (10 mg per mL) in solution for intravenous injection. The label shows a single-dose vial illustration and includes warnings about it being a paralyzing agent causing respiratory arrest. Manufactured by Meitheal Pharmaceuticals Inc., this package contains 10 single-dose vials of 5 mL each. The label emphasizes careful storage and handling instructions.*
FDA Label Image

Principal Display Panel (Atracurium Besylate Injection, USP 100 mg Vial Label)

Principal Display Panel (Atracurium Besylate Injection, USP 100 mg Vial Label)
Atracurium Besylate Injection, USP 100 mg per 10 mL (10 mg per mL) is shown on a label for a 10 mL multi-dose vial. The label emphasizes it is for intravenous injection and includes a warning indicating it is a paralyzing agent. It is labeled for prescription use only and manufactured by Meitheal Pharmaceuticals Inc.*
FDA Label Image

Principal Display Panel – Atracurium Besylate Injection, Usp 100 mg Carton (Atr09 0002 05)

Principal Display Panel – Atracurium Besylate Injection, Usp 100 mg Carton (Atr09 0002 05)
Packaging label for Atracurium Besylate Injection, USP, 100 mg per 10 mL (10 mg per mL) solution for intravenous injection. The label shows a pink and black design with warnings about paralysis and respiratory arrest. It indicates a multi-dose vial package of 10 x 10 mL vials. The labeler is Meitheal Pharmaceuticals Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.